CLDN6 defines a liver-metastatic CMS4 subgroup in colorectal cancer via CLDN6–SRC–FOXO1 signaling and epigenetic reprogramming
Abstract Background Liver-metastatic colorectal cancer (CRC) of the consensus molecular subtype 4 (CMS4) is aggressive and exhibits poor response to cetuximab, particularly in the presence of FBXW7 mutations. Moreover, the CMS4 subtype of metastatic CRC lacks a stable and robust genomic signature for accurately predicting the development of liver metastasis. This study aimed to identify clinically actionable surface drivers of CMS4 progression and to establish a targeted therapeutic strategy. Methods Multicenter clinical cohorts, bulk and single-cell transcriptomic datasets, and multi-omics analyses were integrated to screen candidate surface markers associated with metastatic CRC. Functional studies using CRC cell models examined effects on adhesion, migration, tumor growth, and liver metastasis. RNA-seq, ATAC-seq, ChIP-seq, protein-interaction analyses, and site-directed mutagenesis were combined to delineate downstream signaling and epigenetic mechanisms. A small-molecule screen was further performed to identify compounds disrupting the relevant protein interaction, followed by validation in patient-derived organoid (PDO) and xenograft (PDX) models. Results CLDN6 was enriched in liver-metastatic CMS4 CRC and was associated with FBXW7-mutant tumors and poor clinical outcome. Functionally, CLDN6-positive tumor cells displayed reduced adhesion-related programs, enhanced motility, and increased tumor growth and liver-metastatic colonization. Mechanistically, phosphorylation of CLDN6 at Y196/Y200 promoted binding to the SRC SH2 domain and sustained SRC activation, leading to FOXO1 phosphorylation and cytoplasmic sequestration. Nuclear FOXO1 directly activated adhesion-related genes and induced KDM6B, which reduced H3K27me3-mediated repression at these loci, thereby establishing a transcriptional–epigenetic mechanism linking CLDN6 signaling to loss of tumor-cell adhesion. Disruption of CLDN6 phosphorylation or CLDN6–SRC interaction reversed these effects. AP20187 suppressed CRC PDO viability and enhanced the antitumor activity of oxaliplatin plus cetuximab in the FBXW7-mutant PDX model. Conclusions CLDN6 defines a biologically and therapeutically distinct liver-metastatic CMS4 CRC subgroup. The CLDN6–SRC–FOXO1–KDM6B axis links a surface-associated signaling event to transcriptional and epigenetic repression of adhesion programs, providing a mechanistic basis for targeting CLDN6-associated signaling in FBXW7-mutant CRC.
Authors
- Yongjie Xie (ORCID: https://orcid.org/0009-0003-3595-0866)
- Chunnuan Wu (ORCID: https://orcid.org/0009-0001-8196-4463)
- Qingwu Du
- Feng Liu (ORCID: https://orcid.org/0000-0002-4442-7028)
- Rui Li (ORCID: https://orcid.org/0000-0001-5343-3027)
- Bo Ni (ORCID: https://orcid.org/0009-0000-3795-4148)
- Yaoyao Zhou (ORCID: https://orcid.org/0000-0001-5104-0457)
- Yamei Han
- Chao Liu
- Wenxia Zhao
- Ziyun Liu
- Jie Zhang
- Shihui Cao
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Zhengzhou University (CN)
- Henan Cancer Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1186/s13046-026-03878-1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00